Skip to content
‹ Back to IndustriesHealthcare

Leveraging AI to Improve Patient Outcomes in Healthcare

The importance of providing patients with a fast and accurate diagnosis cannot be overstated – it can be the difference between life and death. Unfortunately, the healthcare system is overwhelmed, and physicians cannot keep up with the overflow of patient needs in a timely manner. Dr. Chai Xiangfei, CEO and co-founder at HY Medical, and…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Intel on MarketScale.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The importance of providing patients with a fast and accurate diagnosis cannot be overstated – it can be the difference between life and death. Unfortunately, the healthcare system is overwhelmed, and physicians cannot keep up with the overflow of patient needs in a timely manner.

Dr. Chai Xiangfei, CEO and co-founder at HY Medical, and Beenish Zia, chief architect of medical imaging at Intel, sit down with podcast host, Tyler Kern, to discuss the current challenges of providing a patient diagnosis in a timely manner and how artificial intelligence (AI) solutions can help.

Beenish discusses and highlights the complexities of diagnosing patient illnesses. “Medical diagnosis is a complex process which requires clinical skills and the need for clear decisions. And it needs to be balanced with acceptance for the ambiguity of many clinical situations,” Beenish explains.

According to Beenish, there are five major obstacles that delay diagnosis:

  1. There are variations in individual logic and processes.
  2. Because the nature of the evidence is not clear, further tests/screenings are required.
  3. Standards vary globally, which causes longer diagnosis times.
  4. Lack of evidence and data from diverse populations leads to not having good data sets to represent different communities.
  5. The number of cases a physician must handle grows daily.

“For example, in certain hospitals in New York, we have heard that the radiologists get more than 1400 scans per day, and maybe there is just like a handful of radiologists to look at them. So, just the huge imbalance between the number of cases requiring diagnosis and the medical staff available to provide the diagnosis is not good,” Beenish explains.

To address this need, Dr. Chai talks about the role of AI in reducing diagnosis time to improve patient outcomes. “There are a huge amount of images created every day. In the meantime, actually, there’s a shortage of radiologists to read images. So, the real situation is that because there is a long waiting list of imaging… it can take hours or even days” for patients to get the result of their tests, notes Dr. Chai.

With traditional processes, scans are taken and added to a waiting list to be read and interpreted by radiologists, which can take up to 15 minutes. Current AI technology can give initial results within one minute and can ultimately reduce reading time by 30%. When radiology staff and doctors get the initial results, they can then quickly review the areas highlighted by the AI and then determine a path forward for diagnosis and treatments. Having this reduction in reading time, is helping patients get treated sooner.

To learn more about how AI can transform the diagnostic process and improve patient outcomes, connect with Dr. Chai Xiangfei and Beenish Zia on LinkedIn.

To find out more about HY Medical please visit: https://www.huiyihuiying.com/#page1.

Learn about various technologies Intel offers to advance the healthcare field — from compute to storage and networking to AI — visit: https://www.intel.com/content/www/us/en/healthcare-it/healthcare-overview.html

Subscribe to this channel on Apple Podcasts, Spotify, and Google Podcasts to hear more from the Intel Internet of Things Group.

Intel

Part of this channel

Intel

Silicon and AI platforms powering enterprise and edge compute.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

AI cuts cardiologists' echocardiogram review time by 46%

AI cuts cardiologists' echocardiogram review time by 46%

Late-breaking research presented November 9 at the American Heart Association's Scientific Sessions 2026 reported that AI-drafted preliminary echocardiogram reports were comparable to human drafts. Cardiologists averaged 4.6 minutes finalizing AI drafts versus 8.5 minutes without AI. The findings are a non-peer-reviewed abstract.

  • 01Cardiologists averaged 4.6 minutes finalizing AI-drafted echo reports versus 8.5 minutes without AI, about 46% less time.
  • 02Cardiologists made substantial changes to 50.6% of AI drafts and 49.7% of human drafts.
  • 03The research used 1,200 echocardiograms from 21 Kaiser Permanente Northern California medical centers.

Nov 9, 2026

Hospitals can meet antibiotic stewardship rules without a full-time ID hire

Hospitals can meet antibiotic stewardship rules without a full-time ID hire

Access TeleCare pharmacist Ashley Selby describes a telehealth antimicrobial stewardship model sized to each hospital's gaps. Joint Commission Standard MM.09.01.01 and 42 CFR 482.42 require a qualified physician and/or pharmacist leader, not a full-time hire, and a 14-study meta-analysis found telehealth stewardship cut antibiotic days of therapy without changing mortality.

  • 01Joint Commission Standard MM.09.01.01, in force since January 2023, requires a physician and/or pharmacist qualified in infectious diseases or stewardship to lead the program, and its committee note allows remote participation.
  • 02The Board of Pharmacy Specialties counts more than 2,380 BCIDP pharmacists nationally, while many small hospitals still assign stewardship to pharmacists without ID training.
  • 03A 14-study meta-analysis found telehealth stewardship raised guideline adherence and cut antibiotic days of therapy, but did not significantly change mortality.

Nov 9, 2026

Caris launches blood-based treatment response monitoring as Q3 revenue rises 27%

Caris launches blood-based treatment response monitoring as Q3 revenue rises 27%

Caris Life Sciences completed approximately 61,500 clinical cases in Q3 2026 and raised 2026 revenue guidance to $1.04-$1.05 billion. Caris Assure is now available for therapeutic response monitoring, and Caris Confirm, a minimal residual disease assay, is targeted to launch before year-end.

  • 01Caris said higher operating expenses were driven primarily by headcount-related costs, research and development investment and marketing.
  • 02Caris Assure is now available for therapeutic response monitoring, and Caris Confirm, a whole genome, tumor-informed assay for minimal residual disease, is targeted to launch before year-end.
  • 03Caris reaffirms its guidance for clinical therapy selection volume growth of approximately 20%.

Nov 8, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512